|
|
|
|
| LEADER |
01609nam a22003855i 4500 |
| 001 |
978-3-7643-7425-9 |
| 005 |
20191024192134.0 |
| 007 |
cr nn 008mamaa |
| 008 |
100301s2008 sz | s |||| 0|eng d |
| 020 |
|
|
|a 9783764374259
|
| 024 |
7 |
|
|a 10.1007/978-3-7643-7425-9
|2 doi
|
| 040 |
|
|
|a Sistema de Bibliotecas del Tecnológico de Costa Rica
|
| 245 |
1 |
0 |
|a Pharmacotherapy of Obesity
|c edited by John P. H. Wilding.
|
| 250 |
|
|
|a 1st ed. 2008.
|
| 260 |
# |
# |
|a Basel :
|b Birkhäuser Basel :
|b Imprint: Birkhäuser,
|c 2008.
|
| 300 |
|
|
|a X, 120 p. 18 illus., 1 illus. in color.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
1 |
|
|a Milestones in Drug Therapy,
|
| 505 |
0 |
|
|a Why drugs? -- Some historical aspects of drug treatment for obesity -- Regulation of energy balance - towards rational drug design in obesity -- Intestinal lipase inhibitors -- Sibutramine -- The endocannabinoid system as a target for obesity treatment -- Using the body's natural signals - gut hormones -- Influencing energy expenditure and substrate utilisation.
|
| 650 |
|
0 |
|a Pharmacology.
|
| 650 |
|
0 |
|a Metabolic diseases.
|
| 650 |
|
0 |
|a Diabetes.
|
| 650 |
|
0 |
|a Cardiology.
|
| 650 |
|
0 |
|a Cell biology.
|
| 650 |
1 |
4 |
|a Pharmacology/Toxicology.
|
| 650 |
2 |
4 |
|a Metabolic Diseases.
|
| 650 |
2 |
4 |
|a Diabetes.
|
| 650 |
2 |
4 |
|a Cardiology.
|
| 650 |
2 |
4 |
|a Cell Biology.
|
| 700 |
1 |
|
|a Wilding, John P. H.
|e editor.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-7643-7425-9
|